Abstract:Objective X‐linked adrenoleukodystrophy (ALD) is caused by mutations in ABCD1, a peroxisomal gene. More than half of males with an ABCD1 mutation develop inflammatory cerebral demyelination (cALD), but underlying mechanisms remain unknown and therapies are limited. We sought to develop and characterize a mouse model of cALD to facilitate study of disease mechanisms and therapy development. Methods We used immunoassays and immunohistochemistry to assess novel (interleukin 18 [IL‐18]) and established molecular markers in cerebrospinal fluid (CSF) and postmortem brain tissue from cALD patients. We generated a cALD phenotype in Abcd1‐knockout mice using a 2‐hit method that combines cuprizone and experimental autoimmune encephalomyelitis models. We then used magnetic resonance imaging (MRI) and immunohistochemistry to assess the fidelity of cALD molecular markers in the mice. Results Human and mouse cALD lesions shared histologic features of myelin phagocytosis, myelin loss, abundant microglial activation, T and B‐cell infiltration, and astrogliosis. Compared to wild‐type controls, Abcd1‐knockout mice displayed more cerebral demyelination, blood–brain barrier disruption, and perivascular immune cell infiltration. This enhanced inflammatory response was associated with higher levels of fibrin deposition, oxidative stress, demyelination, and axonal injury. IL‐18 immunoreactivity co‐localized with perivascular monocytes/macrophages in both human and mouse brain tissue. In cALD patients, CSF IL‐18 levels correlated with MRI lesion severity. Interpretation Our results suggest loss of Abcd1 function in mice predisposes to more severe blood–brain barrier disruption, cerebral inflammation driven by the infiltration of peripheral immune cells, demyelination, and axonal damage, replicating human cALD features. This novel mouse model could shed light on cALD mechanisms and accelerate cALD therapy development. ANN NEUROL 2024

In vivo adenine base editing rescues adrenoleukodystrophy in a humanized mouse model

In Vivo AAV-CRISPR/Cas9–Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia

Therapeutic adenine base editing corrects nonsense mutation and improves visual function in a mouse model of Leber congenital amaurosis

Adenine Base Editing in an Adult Mouse Model of Tyrosinaemia

Elovl1 inhibition reduced very long chain fatty acids in a mouse model of adrenoleukodystrophy

Amelioration of an Inherited Metabolic Liver Disease through Creation of a De Novo Start Codon by Cytidine Base Editing.

Correction of human non-sense mutation via adenine base editing for Duchenne muscular dystrophy treatment in mouse

Intracerebral lentiviral ABCD1 gene therapy in an early disease onset ALD mouse model

Cytosine and Adenine Base Editing of the Brain, Liver, Retina, Heart and Skeletal Muscle of Mice Via Adeno-Associated Viruses

In utero adenine base editing corrects multi-organ pathology in a lethal lysosomal storage disease

In Vivo Base Editing Rescues Primary Hyperoxaluria Type 1 in Rats.

Adenine base editor‐based correction of the cardiac pathogenic Lmna c.1621C > T mutation in murine hearts

In Vivo Base Editing Rescues Hutchinson–Gilford Progeria Syndrome in Mice

Amelioration of Metabolic and Behavioral Defects Through Base Editing in the PahR408W Phenylketonuria Mouse Model

In vivo base editing rescues cone photoreceptors in a mouse model of early-onset inherited retinal degeneration

In Vivo Adenine Base Editing Corrects Newborn Murine Model of Hurler Syndrome

Novel AAV-mediated genome editing therapy improves health and survival in a mouse model of methylmalonic acidemia

A Novel Mouse Model for Cerebral Inflammatory Demyelination in X‐Linked Adrenoleukodystrophy: Insights into Pathogenesis and Potential Therapeutic Targets

ABE8e adenine base editor precisely and efficiently corrects a recurrent COL7A1 nonsense mutation

Enhanced genome editing to ameliorate a genetic metabolic liver disease through co-delivery of adeno-associated virus receptor

In Vivo Genome Editing Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency